TriangleLoncastuximab tesirine 150 µg/Kg (NCT05296070)
Loncastuximab tesirine 150 µg/Kg trial for Marginal Zone Lymphoma (NCT05296070). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults whose marginal zone lymphoma has progressed or failed to respond after treatment that included an anti-CD20 antibody. They must need further treatment and have no prior CD19-directed therapy.
The idea: loncastuximab tesirine delivers a DNA-damaging drug to CD19-bearing cells. Participants receive six intravenous doses, three weeks apart. Researchers measure complete responses at six and twelve months.
This phase 2 study plans 50 patients. Miami’s Izidore Lossos leads it; four US sites are recruiting, including Miami.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.